Allysta doses first patient in phase 1/2a dry eye trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been dosed in a phase 1/2a trial of ALY688, a dry eye treatment candidate, Allysta Pharmaceuticals announced in a press release.

A novel peptide agonist that binds to and activates adiponectin receptors, ALY688 acts to reduce inflammation and promote healing of the cells lining the ocular surface, the release said.

“This marks a significant milestone for Allysta, as we now progress from a preclinical into a clinical-stage company. We look forward to completing this trial by mid-year and reporting data in the second half of 2020,” Henry Hsu, MD, CEO and president of Allysta, said in the release.